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The use of crizotinib in non–small-cell lung cancer (NSCLC) patients harboring anaplas-tic lymphoma kinase (ALK) gene fusions is associated with significant clinical benefit 
and is superior to standard second-line chemotherapy.1 Despite the high response rate and 
durable progression-free survival, crizotinib benefit is limited by eventual tumor progres-
sion. Analysis of tumor specimens obtained from ALK+ NSCLC patients following dis-
ease progression on crizotinib has revealed multiple mechanisms of cellular resistance.2–6 
These include multiple secondary ALK kinase domain mutations that confer resistance to 
crizotinib. Copy number gain (CNG) of the ALK fusion gene compared with pretreatment 
levels has also been observed in both preclinical studies and clinical tumor specimens.2,3,5,7 
Collectively, these two forms of resistance—ALK kinase mutations and ALK fusion CNG—
have been termed ALK-dominant mechanisms of resistance because tumors harboring 
these mechanisms presumably preserve ALK signaling despite the presence of crizotinib 
and are still dependent on that pathway for survival. Consequently, use of a more potent 
second-generation ALK inhibitor may be sufficient to reestablish control of the cancer. In 
contrast, bypass signaling, by v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog (KIT) or epidermal growth factor receptor (EGFR), has also been described as 
a mechanism of resistance to crizotinib in ALK+ NSCLC.2,3 In these ALK nondominant 
tumors, a second-generation ALK inhibitor is predicted to be ineffective given the addi-
tional requirement of inhibiting the bypass signaling mechanisms.
Multiple different ALK kinase domain mutations have been observed in post-
crizotinib tumor samples, including F1174V and G1202R, the two mutations noted in 
a  post-ALK inhibitor tumor specimens by Ou et al in this issue.8 In total, ALK kinase 
domain mutations are estimated to comprise approximately 27% (19 of 70 patients) based 
on results from four studies.4–6,9 ALK fusion CNG has been observed in approximately 
14% (7 of 51) of postcrizotinib specimens, although this mechanism has been observed in 
tumor samples with simultaneous ALK kinase domain mutations in some cases.2,7 Thus, at 
most, only approximately 40% of patients seem to have an ALK-dominant mechanism of 
resistance that might predict for benefit from a second-generation ALK inhibitor. Specific 
ALK mutations, such as G1202R and D1203N, may not respond to these new ALK inhibi-
tors,9,10 as seen in the case described by Ou et al.8 Given that only a proportion of tumor 
shrinkage cases result in objective response criteria per Response Evaluation Criteria in 
Solid Tumors, one might therefore predict objective response rates to second-generation 
ALK inhibitors of 20% to 30%. Nevertheless, data from several second-generation ALK 
inhibitors demonstrate response rates of 55% to 60% in crizotinib-resistant, ALK+ NSCLC 
patients with observed or predicted disease control rates of approximately 90%.11–13 This 
raises the question of why, when we have good rebiopsy-based translational data supported 
by similar observed mechanisms in preclinical models, there is an apparent disconnect with 
the clinical data, that is, why do these inhibitors work so well in what is predicted to be a 
challenging acquired resistance setting?
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Several potential explanations may underlie this fortu-
itous discrepancy (Fig. 1). The small numbers of tumor sam-
ples available for analysis in rebiopsy series means that the 
confidence intervals around the observed frequencies of the 
different resistance mechanisms will be correspondingly wide. 
Consequently, the true frequency of kinase domain mutations 
or CNG may be higher (or lower) than our initial estimates. 
It is hoped that larger proposed series of  crizotinib-resistant, 
ALK+ tumor samples will address this in the near future. In 
addition, some of these mechanisms may exist in tumor sam-
ples but are missed by current analytic techniques. For exam-
ple, direct sequencing suffers a high false-negative rate due 
to allelic dilution.14 Nevertheless, at least one  next-generation 
sequencing study failed to detect higher mutation rates.4 
Different definitions of CNG may generate an underestimate 
of this mechanism of resistance. Mechanisms other than CNG 
may lead to higher protein expression of echinoderm micro-
tubule associated protein like 4 (EML4)-ALK and hence 
increased signaling in the presence of a static dose of crizo-
tinib. Loss of hypothetical negative regulators of ALK activity 
might also lead to improved ALK signaling despite the contin-
ued presence of crizotinib. Serendipitous targeting of another 
kinase responsible for bypass signaling involved in acquired 
resistance could also explain additional responses to therapy. 
One such potential pathway is IGF1R. Increased insulin-like 
growth factor 1 receptor (IGF1R) activity has been observed in 
ALK+ cell lines with induced crizotinib resistance, and some 
of the  second-generation ALK inhibitors, such as ceritinib 
(LDK378) and AP26113, also target IGF1R.15–17 Re-response 
to crizotinib after progression on this drug and subsequent, 
intervening chemotherapy has been observed in two cases and 
could account for additional cases of response to second-gen-
eration inhibitors, although the frequency or mechanism of re-
response is not yet known.18,19 Finally, one could speculate on 
a non–cancer cell intrinsic mechanism that could account for 
a re-response to a new ALK inhibitor following initial crizo-
tinib response and then disease progression, such as decreased 
crizotinib exposure over time. No long-term pharmacokinetic 
data have been published on ALK+ patients receiving crizo-
tinib. Increased liver metabolism or other host-specific factors 
could decrease drug exposure over time.
If we hope to delay or minimalize drug resistance to 
crizotinib or next-generation ALK inhibitors, it will be criti-
cal to understand the mechanisms underlying both our failures 
and successes.
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FIGURE 1.  Discrepancy between 
predicted and observed benefit of 
second-generation ALK inhibitors in 
crizotinib-resistant, ALK+ lung cancer. 
Percentage of ALK-dominant resis-
tance is derived from four indepen-
dent studies that measure ALK kinase 
domain mutations or three indepen-
dent studies that measure CNG by 
fluorescence in situ hybridization. 
One patient had both an ALK kinase 
domain mutation and CNG (*). ORR 
and DCR are shown for indicated 
 second-generation ALK inhibitors. 
CNG, copy number gain; ORR, 
objective response rate; DCR, disease 
control rate; RECIST, Response 
Evaluation Criteria in Solid Tumors.
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